Methodology A survey was prepared using the ‘SurveyMonkey’ application and distributed across gynecological oncology groups using social media platforms from 2nd October to 8th November 2022. There were 21 survey questions; 6 on demography and 15 on diagnosis and management. Descriptive statistics including frequencies and percentages were used to report data and analyses were performed using SPSS version 25.

Results There were a total of 203 responses from 50 countries across 6 continents. The majority responding to the survey were gynecological oncologists (73.10%). Only 29.56% of institutions used immunohistochemistry along with tissue morphology for diagnosis. 55.78% of practitioners offered platinum-based Neoadjuvant Chemotherapy for newly diagnosed apparent Stage III C disease seemingly inoperable. 44.83% of practitioners offered adjuvant Chemotherapy (± Bevacizumab) followed by hormonal maintenance (HM) for advanced stage after optimal cytoreduction. Letrozole was the preferred drug (63.37%). In recurrent settings not feasible for secondary cytoreduction, there was a lack of consensus on further management. Regarding targeted therapy, 83% of practitioners had never used MEK inhibitors in practice. In patients desirous for fertility preservation in sub-optimally staged apparent Stage IA LGSOC, most clinicians (71%) offered completion staging with preservation of the uterus and other ovary followed by observation if histologically confirmed Stage IA. Regarding adjuvant treatment for optimally staged IC disease, there were varied opinions ranging from observation, chemotherapy alone, chemotherapy followed by HM or HM alone. The use of HIPEC in any setting was not favored by the majority (81.26%). A majority (45.32%) of practitioners didn’t offer routine genetic testing in all cases.

Conclusion There are global similarities and disparities regarding the management of LGSOC. These factors may be considered while formulating international guidelines.

Methodology All women diagnosed with EOC, stage IIC-IV and registered in the Swedish Quality Register for Gynecologic Cancer between 2008–2018 with PDS performed followed by chemotherapy were included. Patient and tumor characteristics including no (R0) or residual disease (RD), were retrieved. The TTC was categorized into five groups. The 2- and 5-year RS (95%CI) were calculated and uni- and multivariable Poisson regression of excess mortality rate ratios (EMRRs) analyzed with covariates; TTC, age, FIGO stage, serous and non-serous histology and residual disease.

Results In total, 1710 women were included. The mean age was 64.3 years. R0 was achieved in 47.7%; 39.0% of 292 women with TTC < 21 days, 46.9% of 360 with 22–28 days, 48.5% of 392 (29–35 days), 52.1% of 303 with 36–42 days and 51.0% of 363 women with TTC > 42 days, respectively. In the total cohort, age < 70 years, stage IIC, serous histology and R0 were found significant prognostic factors for 5-year RS but not TTC. Two-year RS for FIGO stage IV and R0 was 92.9% (82.8–1.00) for TTC < 21 days compared with 66.3% (50.8–81.8) for TTC > 42 days. The corresponding figures for stage IIC and R0 were 91.0% (84.7–97.4) and 82.4% (75.8–89.0), respectively. Five-year RS for FIGO stage IV and R0 was 67.2% (48.0–86.3) for TTC < 21 days and 42.6% (25.2–59.9) for TTC > 42 days. The corresponding 5-year RS for stage IIC and R0 were 56.4% (45.2–67.6) and 51.6% (42.8–60.5), respectively.

Conclusion Our data indicate that TTC after PDS may be associated with short-term survival among stage IV disease without residual disease. Updated results with EMRR data for subgroups will be presented.

Disclosures The authors declare no conflicts of interest.

#652 HAS TIME TO CHEMOTHERAPY FROM PRIMARY DEBULKING SURGERY IN ADVANCED OVARIAN CANCER AN IMPACT ON SURVIVAL? – A POPULATION-BASED NATIONWIDE SWEGCG STUDY

1Perrina Dahm-Kähler*, 2Angelique Flöter Rädestad, 3Erik Holmberg, 4Chister Borgfeldt, 5Maria Bjurborg, 6Camilla Sköld, 7Kristina Hellman, 8Preben Kjølhede, 9Karin Stålberg, 10Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden; 11Department of Obstetrics and Gynecology, Karolinska Institute, Stockholm, Sweden; 12Regional Cancer Center Western, Gothenburg, Sweden; 13Department of Obstetrics and Gynecology, Skåne University Hospital, and Department of Clinical Sciences, Lund University, Lund, Sweden; 14Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund University, Lund, Sweden; 15Department of Oncology, Uppsala University Hospital, Uppsala, Sweden; 16Department of Oncologic Gynecologic Cancer, Karolinska University Hospital, Stockholm, Sweden; 17Department of Obstetrics and Gynecology, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; 18Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden; 19Department of Oncology, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden

10.1136/ijgc-2023-ESGO.32

Introduction/Background To investigate time to chemotherapy (TTC) from primary debulking surgery (PDS) and relative survival (RS) in advanced epithelial ovarian cancer (EOC) in a nationwide population-based cohort.

#682 ROLE OF LYMPHADENECTOMY (LND) IN ADVANCED OVARIAN CANCER (OC) – A SUBGROUP ANALYSIS OF THE PATIENTS EXCLUDED FROM THE ORIGINAL LION TRIAL (THE CHARITÉ COHORT)

1Robert Armbrecht*, 2Christina Fotopoulou, 3Radoslaw Cherekov, 4Zitul Mustafa Mualliem, 5Ionna Braicu, 6Klaus Pietzner, 3Philipp Hater, 7Jaded Seshouli, 8Department of Gynecology with Center for Oncological Surgery, Charité University Hospital Berlin, Berlin, Germany; 9Imperial College London, London, UK; 10Klinikum Essen Mitte, Essen, Germany

10.1136/ijgc-2023-ESGO.33

Introduction/Background The results of the prospective randomized phase-III LION-trial failed to demonstrate a therapeutic benefit from LND in tumor-free operated advanced OC patients with macroscopically normal appearing LN. Patients were randomized intraoperatively with exclusion of those thought by the surgeon not to be fully operable or with suspicious/bulky LN by inspection or palpation. We wished to address the surgical and survival outcomes of this excluded group in a single center.

Methodology This is a monocentric analysis in a tertiary ESGO-accredited center of excellence for OC. A total of 202 patients were screened for the original study; 120 were excluded, and 82 included in the final LION analysis. Excluded cases were retrospectively analyzed according to the same endpoints (PFS and OS) of the LION-trial with a subsequent comparison analysis.

Results Overall, 195 patients were included in the present analysis. Rate of CR was with 45% significantly lower in the intraoperatively excluded patients vs the tumor-free operated patients of the original LION analysis. This had a significantly